Isoliquiritigenin Suppressed Esophageal Squamous Carcinoma Growth by Blocking EGFR Activation and Inducing Cell Cycle Arrest

Plant leads for mitigation of oral submucous fibrosis: Current scenario and future prospect

The aim of this review is to enumerate medicinal plants and their bioactive compounds that may become potential leads in the mitigation of oral submucous fibrosis (OSMF) in the forthcoming future. It is focused on pathophysiology, risk factors, current treatment regimen, potential plant leads, and future therapies for OSMF. Data were extracted from a vast literature survey by using SciFinder, Web of Science, Google Scholar, and PubMed search engines with relevant keywords. Upon literature survey, we found that the phytochemical 'arecoline' present in the areca nut is the main causative agent of OSMF condition. Currently, OSMF is treated by immunomodulatory and anti-inflammatory agents such as corticosteroids, enzymes (hyaluronidase, chymotrypsin, and collagenase), anti-inflammatory mediators (isoxsuprine and pentoxifylline), dietary supplements (vitamins, antioxidants, and micronutrients), and anti-fibrotic cytokines like interferon-gamma that provides short-term symptomatic relief to OSMF patients. However, some plant leads have been proven effective in alleviating symptoms and mitigating OSMF, which ultimately improves the quality of OSMF patients' life. We concluded that plant drugs like lycopene, curcumin, Aloe vera, colchicine, and Glycyrrhiza glabra are effective against OSMF in various in vitro and/or clinical studies and are being used by modern and traditional practitioners.

The Potential of Glycyrrhiza from "Medicine Food Homology" in the Fight against Digestive System Tumors

Glycyrrhiza has a long history of applications and a wide range of pharmacological effects. It is known as the "king of all herbs". Glycyrrhiza is effective in clearing heat, detoxifying, relieving cough, and tonifying qi and has good bioactivity in multiple inflammatory, immune, and tumor diseases. This review aims to summarize the origin, distribution, and anti-digestive system tumor mechanism of glycyrrhiza and its homologous applications in medicine and food. The active compounds include triterpenoids, flavonoids, and coumarins, which are widely used in clinical treatments, disease prevention, and daily foods because of their "enhancement of efficacy" and "reduction of toxicity" against digestive system tumors. This paper reviews the use of glycyrrhiza in digestive system tumors and provides an outlook on future research and clinical applications.

Natural Products for Esophageal Cancer Therapy: From Traditional Medicine to Modern Drug Discovery

Esophageal cancer (EC) is one of the most malignant types of cancer worldwide and has a high incidence and mortality rate in Asian countries. When it comes to treating EC, although primary methods such as chemotherapy and surgery exist, the prognosis remains poor. The purpose of this current research is to review the range of effects that natural products have on cancer by analyzing studies conducted on EC. Fifty-seven studies were categorized into four anti-cancer mechanisms, as well as clinical trials. The studies that were scrutinized in this research were all reported within five years. The majority of the substances reviewed induced apoptosis in EC, acting on a variety of mechanisms. Taken together, this study supports the fact that natural products have the potential to act as a candidate for treating EC.

Long noncoding RNA DANCR expression and its predictive value in patients with atherosclerosis

Long noncoding RNAs (lncRNAs) act crucial roles in the progression of vascular diseases, including atherosclerosis. This study aims to investigate the expression levels of the atherosclerosis-associated lncRNA DANCR in patients diagnosed with atherosclerosis and whether its abnormal expression affects the progress of atherosclerosis. The expression of DANCR in the serum samples of all study participants was quantified using RT-qPCR. Then, the predictive capacities of DANCR for the detection of atherosclerosis patients were evaluated via receiver operating characteristic (ROC) curve analysis. The effects of DANCR on vascular smooth muscle cells (VSMCs) proliferation and migration were then explored using cell counting kit-8 (CCK-8) and Transwell migration assays. The DANCR exhibited increased expression trends in patients with atherosclerosis than healthy controls. Moreover, there were differences in the levels of low-density lipoprotein cholesterol (LDL-C), homocysteine (Hcy), and C-reactive protein (CRP) between the healthy controls and atherosclerosis patients. The DANCR expression was positively correlated with serum LDL-C, Hcy, and CRP levels. DANCR expression could distinguish patients with atherosclerosis from healthy individuals with a high area under the ROC curve (AUC), sensitivity, and specificity. Additionally, knockdown of DANCR weakened the proliferative abilities and migration capacities of VSMCs. It was also shown that DANCR could compete with miR-335-5p binding. Herein, it appears that the LncRNA DANCR was closely associated with the progression of atherosclerosis by targeting miR-335-5p, which might be a potential detective predictor and target for the treatment of atherosclerosis.